Kempen is pleased to announce that it acted as Co-Manager in Genmab’s Initial Public Offering on the Nasdaq Global Select Market, successfully raising c. USD 582m
Genmab is a biotechnology company specializing in the development of differentiated antibody therapeutics for the treatment of cancer. The company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers and amyloidosis. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline and a number of proprietary next generation antibody technologies. Genmab is based in Copenhagen, Denmark and has alliances with other leading pharmaceutical and biotechnology companies.